Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies

Pediatrics International

Volumn 54, Issue 2, 2012, Pages 285-287

  Fuchimoto, Yasushi ^a   Morikawa, Nobuyuki ^c   Kuroda, Tatsuo ^c   Hirobe, Seiichi ^b   Kamagata, Shouichiro ^b   Kumagai, Masaaki ^c   Matsuoka, Kentaro ^c   Morikawa, Yasuhide ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

actinomycin D and cyclophosphamide therapy; infant; kaposiform hemangioendothelioma; Kasabach Merritt syndrome; vincristine

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ANEMIA; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; CANCER RADIOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEMANGIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; KASABACH MERRITT SYNDROME; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; REMISSION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; HEMANGIOENDOTHELIOMA; HUMANS; INFANT, NEWBORN; KASABACH-MERRITT SYNDROME; MALE; PLATELET COUNT; SARCOMA, KAPOSI; TREATMENT FAILURE; VINCRISTINE;

EID: 84859923013     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2011.03414.x     Document Type: Article

References (13)

1. Enjolras O, Wassef M, Dosquet C, et al,. [Kasabach-Merritt syndrome on a congenital tufted angioma]. Ann. Dermatol. Venereol. 1998; 125: 257-60.
2. Hall GW,. Kasabach-Merritt syndrome: Pathogenesis and management. Br. J. Haematol. 2001; 112: 851-62.
3. Moore J, Lee M, Garzon M, et al,. Effective therapy of a vascular tumor of infancy with vincristine. J. Pediatr. Surg. 2001; 36: 1273-6.
4. Taki M, Ohi C, Yamashita A, et al,. Successful treatment with vincristine of an infant with intractable Kasabach-Merritt syndrome. Pediatr. Int. 2006; 48: 82-4.
5. Thomson K, Pinnock R, Teague L, Johnson R, Manikkam N, Drake R,. Vincristine for the treatment of Kasabach-Merritt syndrome: Recent New Zealand case experience. N. Z. Med. J. 2007; 120 (1249): U2418.
6. Yesudian PD, Klafkowski J, Parslew R, Gould D, Lloyd D, Pizer B,. Tufted angioma-associated Kasabach-Merritt syndrome treated with embolization and vincristine. Plast. Reconstr. Surg. 2007; 119: 1392-3.
7. Hu B, Lachman R, Phillips J, Peng SK, Sieger L,. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J. Pediatr. Hematol. Oncol. 1998; 20: 567-9.
8. Vin-Christian K, McCalmont TH, Frieden IJ,. Kaposiform hemangioendothelioma. An aggressive, locally invasive vascular tumor that can mimic hemangioma of infancy. Arch. Dermatol. 1997; 133: 1573-8.
9. Haisley-Royster C, Enjolras O, Frieden IJ, et al,. Kasabach-Merritt phenomenon: A retrospective study of treatment with vincristine. J. Pediatr. Hematol. Oncol. 2002; 24: 459-62.
10. Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC,. Vincristine as a treatment for a large haemangioma threatening vital functions. Br. J. Plast. Surg. 2004; 57: 168-71.
11. Perez J, Pardo J, Gomez C,. Vincristine: An effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002; 41: 197-9.
12. Saito M, Gunji Y, Kashii Y, et al,. Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: A case report [Case Reports]. J. Pediatr. Hematol. Oncol. 2009; 31: 194-7.
13. Gottschling S, Schneider G, Meyer S, Reinhard H, Dill-Mueller D, Graf N,. Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr. Blood Cancer 2006; 46: 239-42.